-
A Treatment That Came Just in TimeCancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
More Data on COVID-19 Vaccination and CancerStudies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Building COVID-19 Vaccine ConfidenceExperts discussed how the cancer community can share accurate information and increase confidence in COVID-19 vaccines, both among people with cancer and the general population.
by Kevin McLaughlin
-
Searching the Blood for Signs of Altered ImmunityThe immune systems of people with blood cancer respond differently to infection with the coronavirus than the immune systems of people without cancer or with solid tumors.
by Kate Yandell
-
A Drive for DiversityAfrican Americans are underrepresented in the Be The Match bone marrow donor registry. Patient advocates are working to change that.
by Jon Kelvey
-
Cancer and COVID-19 VaccinationAmid continued research showing the impact of COVID-19 on people with cancer, patients are asking when they should get a COVID-19 vaccine.
by Marci A. Landsmann
-
Despite Generic Imatinib, Cost of Treating CML Remains HighThe arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.
by Anna Azvolinsky
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
